Latigo Biotherapeutics

Latigo Biotherapeutics Announces Pricing of Upsized $345.6 Million Initial Public Offering

THOUSAND OAKS, Calif., August 6, 2026 – Latigo Biotherapeutics, Inc. (“Latigo”), a clinical-stage biopharmaceutical company committed to developing innovative non-opioid pain medicines, today announced the pricing of its upsized initial public offering of 19,200,000 shares of common stock at a…

Latigo Biotherapeutics Announces New England Journal of Medicine Publication of Positive LTG-001 Abdominoplasty Clinical Trial Results in Moderate-to-Severe Acute Pain

Results demonstrated statistically significant pain reduction, rapid onset of analgesia, and opioid-sparing potential of investigational selective Nav1.8 inhibitor LTG-001 Marks only the second original research publication in the New England Journal of Medicine reporting clinical results for a…

Latigo Biotherapeutics Appoints Todd Smith to its Board of Directors

Veteran biopharmaceutical executive brings extensive commercial and product launch expertise THOUSAND OAKS, Calif. – July 8, 2026 – Latigo Biotherapeutics, Inc. (Latigo), a clinical-stage biopharmaceutical company committed to developing innovative non-opioid pain medicines, today announced the…

Latigo Biotherapeutics Appoints Sara M. Bonstein to its Board of Directors and as Audit Committee Chair

Experienced chief financial officer brings deep financial and strategic leadership to Latigo’s board of directors Appointment supports continued operational growth THOUSAND OAKS, Calif. — April 8, 2026 — Latigo Biotherapeutics, Inc. (Latigo), a clinical-stage biopharmaceutical company committed to…

Latigo Biotherapeutics Appoints Neha Krishnamohan as Chief Financial Officer and Chief Business Officer

Veteran biotech leader with more than 15 years of experience joins as Latigo advances non-opioid pain pipeline Appointment comes as Latigo builds toward late-stage development and broader corporate milestones THOUSAND OAKS, Calif. — March 3, 2026 — Latigo Biotherapeutics, Inc. (Latigo), a…

Latigo Biotherapeutics Closes $150 Million in Series B Financing to Advance Non-Opioid Pain Therapeutics

Financing led by funds managed by Blue Owl Capital; Senior Managing Director Kevin Raidy joins Latigo’s board Proceeds support advancement of company’s Nav1.8 inhibitor clinical programs and development of broader pipeline THOUSAND OAKS, Calif. – March 17, 2025 – Latigo Biotherapeutics (“Latigo”),…